Hepatocellular Carcinoma Clinical Trial
— DUET-2Official title:
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Verified date | November 2022 |
Source | Xencor, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.
Status | Completed |
Enrollment | 150 |
Est. completion date | September 6, 2022 |
Est. primary completion date | June 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of one of the following advanced solid tumors: PART A (Dose Escalation Cohorts) 1. Melanoma; 2. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative (triple-negative breast cancer; TNBC); 3. Hepatocellular carcinoma; 4. Urothelial carcinoma; 5. Squamous cell carcinoma of the head and neck; 6. Renal cell carcinoma (clear cell predominant type); 7. Microsatellite instability-high or mismatch repair deficient colorectal carcinoma or endometrial carcinoma; 8. Non-small cell lung carcinoma; 9. Gastric or gastroesophageal junction adenocarcinoma 10. Mesothelioma; 11. High-grade neuroendocrine carcinoma, including small cell carcinoma of the lung 12. Cervical cancer; 13. Squamous cell carcinoma of the anus PART B (Dose Expansion Cohorts): 1. Melanoma 2. Renal cell carcinoma (clear cell predominant type) 3. Non-small cell lung carcinoma 4. Castrate-resistant adenocarcinoma of the prostate, defined as progressive disease after surgical castration, or progression in the setting of medical androgen ablation with a castrate level of testosterone (< 50 ng/dL) 5. Nasopharyngeal carcinoma 6. Cholangiocarcinoma 7. Basal cell carcinoma 8. Squamous cell carcinoma of the anus 9. Mesothelioma 10. Ovarian or fallopian tube carcinoma 11. Malignant adnexal neoplasms (including, but not limited to, sebaceous carcinoma, trichilemmal carcinoma, pilomatrix carcinoma, eccrine carcinoma, hidradenocarcinoma, adnexal carcinoma with divergent differentiation, papillary digital eccrine adenocarcinoma, microcystic adnexal carcinoma, and clear cell eccrine carcinoma) 12. Thymoma 13. Thymic carcinoma 14. Squamous cell carcinoma of the penis 15. Neuroendocrine carcinoma 16. Vulvar cancer 17. Non-squamous cell salivary gland carcinoma (except adenoid cystic carcinoma) 18. Subjects with other solid tumors for which there is published evidence of anti-tumor activity with anti-PD1/PDL1 and/or anti-CTLA4-directed therapy but for which there is no FDA-approved anti-PD1/PDL1 or CTLA4-directed checkpoint inhibitor treatment may be eligible for Part B after approval by the Medical Monitor. - All subjects' cancer must have progressed after treatment with all standard therapies or have no appropriate available therapies. - Subjects, except those with adenocarcinoma of the prostate, must have measurable disease by RECIST 1.1. - Have available adequate archival formalin-fixed paraffin-embedded block(s)/slides containing tumor or adequate pre-dose fresh tumor biopsy tissue - ECOG performance status of 0 - 1 - Subjects with adenocarcinoma of the prostate must have evaluable disease (measurable or nonmeasurable lesions) by PCWG3. Exclusion Criteria: - Subjects currently receiving other anticancer therapies, with the exception of subjects with adenocarcinoma of the prostate, who may continue luteinizing hormone-releasing hormone (LHRH) analogue therapy. - Treatment with any CTLA4 antibody within 6 weeks of the start of study drug. - Treatment with nivolumab or any PDL1 or PDL2-directed antibody within 4 weeks of the start of study drug. - Treatment with pembrolizumab within 4 - 12 weeks of the start of study drug (cohort dependent). - Treatment with any other anticancer therapy within 2 weeks of the start of study drug (i.e., other immunotherapy, chemotherapy, radiation therapy, etc.). Subjects with prostate cancer may continue LHRH analogue therapy. - A life-threatening (Grade 4) immune-mediated AE related to prior immunotherapy. - Failure to recover from any immune-related toxicity from prior cancer therapy to = Grade 1, except if previous immune-related endocrinopathy is medically managed with hormone replacement therapy only. - Failure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to = Grade 2. - Have known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, are without evidence of progression for at least 4 weeks by repeat imaging, are clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment. - Active known or suspected autoimmune disease (except that subjects are permitted to enroll if they have vitiligo; type 1 diabetes mellitus or residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and non-steroidal anti-inflammatory drugs). - Has any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug (except that inhaled or topical corticosteroids or brief courses of corticosteroids given for prophylaxis of contrast dye allergic response are permitted). - Receipt of an organ allograft. - Prior treatment with any checkpoint inhibitor therapy regimen that targets both PD1/L1 and CTLA-4. |
Country | Name | City | State |
---|---|---|---|
United States | Emory University | Atlanta | Georgia |
United States | Emily Couric Clinical Cancer Center | Charlottesville | Virginia |
United States | University of Chicago Medicine | Chicago | Illinois |
United States | Karmanos Cancer Institute | Detroit | Michigan |
United States | The University of Kansas Clinical Research Center | Fairway | Kansas |
United States | The University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute | Los Angeles | California |
United States | UCLA Hematology-Oncology Clinic (Westwood) | Los Angeles | California |
United States | Columbia University Medical Center - Herbert Irving Pavilion | New York | New York |
United States | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York | New York |
United States | Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania |
United States | UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania |
United States | Providence Portland Medical Center | Portland | Oregon |
United States | University of Utah, Huntsman Cancer Institute | Salt Lake City | Utah |
United States | University of California San Diego Moores Cancer Center | San Diego | California |
United States | University of California San Francisco Medical Center | San Francisco | California |
United States | Seattle Cancer Care Alliance | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Xencor, Inc. | ICON plc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine the safety and tolerability profile of XmAb20717 | Treatment-related adverse events as assessed by CTCAE v4.03 | 56 Days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |